Clinical Trial "PDEIV inhibitors in the treatment of COPD - the Roflumilast Trials"
Symposium Chairs: T. Welte (Hanover, Germany), B. Lipworth (Dundee, United Kingdom)
Aims: To determine whether using the PDEIV inhibitor Roflumilast improves lung function and reduces exacerbation frequency in selected groups of COPD patients. To establish whether this effect was independent of therapy with long-acting bronchodilators.